Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)
Deciphering the mechanisms of the pathogenesis of immune-mediated inflammatory rheumatic diseases (IIRDs) and designing a wide range of biological agents (BAs) are the major achievements of 21st century medicine. A new promising area of pharmacotherapy for IIRDs is associated with the design of so-c...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Russo |
| Argitaratua: |
IMA PRESS LLC
2020-02-01
|
| Saila: | Научно-практическая ревматология |
| Gaiak: | |
| Sarrera elektronikoa: | https://rsp.mediar-press.net/rsp/article/view/2845 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|